Apr 27, 2026
HK inno.N, Atomatrix partner on AI-based obesity drug development
HK inno.N has entered a partnership with Atomatrix to leverage AI in the development of innovative obesity treatments.This collaboration aims to explore small-molecule candidates that utilize new mechanisms of action, moving away from the prevalent incretin-based therapies in the obesity market. HK inno.N will handle drug synthesis and biological evaluation, focusing on the efficacy and safety of the compounds, while Atomatrix will utilize its proprietary CANDDIE platform for molecule design and